Drug intelligence / Profile preview

FY26

Development stage: Preclinical
Lead developer: University of Warwick
Modality: Small Molecules

Overview

FY26 is an organo-osmium compound and a cancer drug candidate currently in preclinical development. Developed by researchers at the University of Warwick, it functions by disrupting cancer cell metabolism. Preclinical in-vitro tests conducted by the Wellcome Trust Sanger Institute and the U.S. National Cancer Institute demonstrated that FY26 was 49 times more potent than cisplatin against cancer cell lines.

Beyond the preview

Go deeper on FY26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FY26.

Explore the full profile